Catalog No.
FHC31212
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
PE
Target
SLC3A2, 4F2hc, Lymphocyte activation antigen 4F2 large subunit, CD98, 4F2 cell-surface antigen heavy chain, Solute carrier family 3 member 2, MDU1, 4F2 heavy chain antigen
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
P08195
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
Ab110
Targeting LAT1 with JPH203 to reduce TNBC proliferation and reshape suppressive immune microenvironment by blocking essential amino acid uptake., PMID:40379991
Suppression of NF-κB and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion., PMID:40073262
Comparative Radiotracing Quantifies Brain Cellular Uptake and Catabolism of Bispecific Antibodies Targeting Transferrin Receptor and CD98hc., PMID:40071777
A genome wide CRISPR screen reveals novel determinants of long-lived plasma cell secretory capacity., PMID:40060628
AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity., PMID:40046051
Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution., PMID:39979268
Expression rate of LAT1 in high-grade parotid gland carcinoma and potential of BNCT as a treatment option for recurrent parotid gland carcinoma., PMID:39837206
Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors., PMID:39755583
Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression., PMID:39639312
Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors., PMID:39600127
Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners., PMID:39433176
A monoclonal antibody recognizing CD98 on human embryonic stem cells shows anti-tumor activity in hepatocellular carcinoma xenografts., PMID:39261363
CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy., PMID:39095551
Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development., PMID:39061168
Upregulation of Transferrin Receptor 1 (TfR1) but Not Glucose Transporter 1 (GLUT1) or CD98hc at the Blood-Brain Barrier in Response to Valproic Acid., PMID:39056763
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy., PMID:39041287
Multilayered proteomics reveals that JAM-A promotes breast cancer progression via regulation of amino acid transporter LAT1., PMID:38943512
Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia., PMID:38914715
CD147 regulates the formation and function of immune synapses., PMID:38909549
Comparative single-cell multiplex immunophenotyping of therapy-naive patients with rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus shed light on disease-specific composition of the peripheral immune system., PMID:38726007
Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy., PMID:38460518
Functional and Immunologic Mapping of Domains of the Reticulocyte-Binding Protein Plasmodium vivax PvRBP2a., PMID:38441336
Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade., PMID:38429349
HERV-K (HML-2) Envelope Protein Induces Mitochondrial Depolarization and Neurotoxicity via Endolysosome Iron Dyshomeostasis., PMID:38383499
The role of EDIL3 in maintaining cartilage extracellular matrix and inhibiting osteoarthritis development., PMID:38081212
Targeted transport of biotherapeutics at the blood-brain barrier., PMID:38059358
CD147: an integral and potential molecule to abrogate hallmarks of cancer., PMID:38023152
Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer., PMID:37731509
Comprehensive cell surface protein profiling of human mesenchymal stromal cells from peritoneal dialysis effluent and comparison with those from human bone marrow and adipose tissue., PMID:37603218
CD98hc is a target for brain delivery of biotherapeutics., PMID:37598178
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer., PMID:37559159
Early appearance of functional plasma cells (CD138+CD98+) in non-immunized neonate mice., PMID:37225058
Unraveling CD69 signaling pathways, ligands and laterally associated molecules., PMID:37223078
Advanced Boron Neutron Capture Therapy Targeting Cancer Stem Cells by Selective Induction of LAT1 Overexpression., PMID:37212749
CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2/CD98 antibody inhibits the growth signal of human breast cancer cells., PMID:36811310
An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice., PMID:36424464
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis., PMID:36257298
HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition., PMID:36151255
Endocytosis-Independent and Cancer-Selective Cytosolic Protein Delivery via Reversible Tagging with LAT1 substrate., PMID:35789055
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study., PMID:35628616
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy., PMID:35577502
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer., PMID:35317825
Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain., PMID:35171652
Galectin-3 enhances atrial remodelling and arrhythmogenesis through CD98 signalling., PMID:34995420
Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer., PMID:34981670
Plasma Membrane Receptors Involved in the Binding and Response of Osteoclasts to Noncellular Components of the Bone., PMID:34576260
Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target., PMID:34194623
Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2., PMID:34112739
Biological drug and drug delivery-mediated immunotherapy., PMID:33996408
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy., PMID:33974508
For research use only. Not for human or drug use.
